World Journal of Hepatology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

JOURNAL HOME

Number of total visits: 2812968

Number of visits today: 17

Number of downloads: 2063811

MEMBERSHIP

BPG JOURNALS

Cited by in F6Publishing

For:	Grubczak K, Kretowska-Grunwald A, Groth D, Poplawska I, Eljaszewicz A, Bolkun L, Starosz A, Holl JM, Mysliwiec M, Kruszewska J, Wojtukiewicz MZ, Moniuszko M. Differential Response of MDA-MB-231 and MCF-7 Breast Cancer Cells to In Vitro Inhibition with CTLA-4 and PD-1 through Cancer-Immune Cells Modified Interactions. Cells 2021;10:2044. [PMID: 34440813 DOI: 10.3390/cells10082044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]

For:

Grubczak K, Kretowska-Grunwald A, Groth D, Poplawska I, Eljaszewicz A, Bolkun L, Starosz A, Holl JM, Mysliwiec M, Kruszewska J, Wojtukiewicz MZ, Moniuszko M. Differential Response of MDA-MB-231 and MCF-7 Breast Cancer Cells to In Vitro Inhibition with CTLA-4 and PD-1 through Cancer-Immune Cells Modified Interactions. Cells 2021;10:2044. [PMID: 34440813 DOI: 10.3390/cells10082044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]

Number	Citing Articles
1	Yao F, An Y, Lai X, Li X, Yu Z, Yang XD. Novel nanotherapeutics for cancer immunotherapy by CTLA-4 aptamer-functionalized albumin nanoparticle loaded with antihistamine. J Cancer Res Clin Oncol 2023. [PMID: 36966395 DOI: 10.1007/s00432-023-04698-y] [Reference Citation Analysis]
2	Mohammed EE, Türkel N, Yigit UM, Dalan AB, Sahin F. Boron Derivatives Inhibit the Proliferation of Breast Cancer Cells and Affect Tumor-Specific T Cell Activity In Vitro by Distinct Mechanisms. Biol Trace Elem Res 2023. [PMID: 36940038 DOI: 10.1007/s12011-023-03632-0] [Reference Citation Analysis]
3	Qaddoori MH, Al-Shmgani HS. Galangin-Loaded Gold Nanoparticles: Molecular Mechanisms of Antiangiogenesis Properties in Breast Cancer. Int J Breast Cancer 2023;2023:3251211. [PMID: 36844680 DOI: 10.1155/2023/3251211] [Reference Citation Analysis]
4	Park YJ, Yoon G, Suh J, Jo BS, Lee DW, Kim D, Choi M, Jeong EK, Lee HC, Lee J, Chung CP, Park YS. Synthetic cell-penetrating RAS-binding peptide for the treatment of KRAS-mutated cancer.. [DOI: 10.21203/rs.3.rs-2394020/v1] [Reference Citation Analysis]
5	Kaproń B, Płazińska A, Płaziński W, Plech T. Identification of the first-in-class dual inhibitors of human DNA topoisomerase IIα and indoleamine-2,3-dioxygenase 1 (IDO 1) with strong anticancer properties. Journal of Enzyme Inhibition and Medicinal Chemistry 2023;38:192-202. [DOI: 10.1080/14756366.2022.2140420] [Reference Citation Analysis]
6	Ghemrawi R, Khair M, Hasan S, Aldulaymi R, AlNeyadi SS, Atatreh N, Ghattas MA. The Discovery of Potent SHP2 Inhibitors with Anti-Proliferative Activity in Breast Cancer Cell Lines. Int J Mol Sci 2022;23:4468. [PMID: 35457286 DOI: 10.3390/ijms23084468] [Reference Citation Analysis]
7	An Y, Li X, Yao F, Duan J, Yang XD. Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo. Molecules 2022;27:1482. [PMID: 35268583 DOI: 10.3390/molecules27051482] [Reference Citation Analysis]